Medtronic sees profit slip despite uptick in revenue

Medtronic ($MDT) pulled in $4.1 billion in revenue last quarter, but charges, litigation costs and expenses dragged profits down by about 25%.

The devicemaker posted $646 million in net profit in the fiscal second quarter, down from $864 million in the same period last year. Quarterly revenue ticked up 2%, sped along by growth in the company's cardiac and vascular and restorative therapies businesses.

Notably, Medtronic grossed $429 million from its coronary devices, a 14% jump, and $344 million from surgical technologies, good for a 15% boost over last year. However, that growth comes amid continued declines for some of the company's largest segments, including defibrillators, which fell 3%, and spinal devices, which notched a 7% revenue decline.

Medtronic CEO Omar Ishrak rarely misses a chance to affirm the company's commitment to growing its emerging markets presence, and the devicemaker did just that in Q2, picking up $464 million from the likes of China and India, a 14% increase over the same period last year.

"Our growth was broad-based across several businesses and geographies, driven by continued stabilization of our end markets and the ongoing successful execution of new product launches," Ishrak said in a statement.

Among those launches and globe-spanning growth spurts, Medtronic is inching toward European approval for its Engager heart valve, looking to unseat Edwards Lifesciences ($EW) in that market, and the company has made a series of big bets in China, closing an $816 million deal for a devicemaker there.

- read Medtronic's release
- check out the full results (PDF)

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.